0001358403-18-000050.txt : 20180529 0001358403-18-000050.hdr.sgml : 20180529 20180529164959 ACCESSION NUMBER: 0001358403-18-000050 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180525 FILED AS OF DATE: 20180529 DATE AS OF CHANGE: 20180529 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Musso Alan A CENTRAL INDEX KEY: 0001295830 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36783 FILM NUMBER: 18865185 MAIL ADDRESS: STREET 1: C/O TARGACEPT, INC. STREET 2: 200 EAST FIRST STREET, SUITE 300 CITY: WINSTON-SALEM STATE: NC ZIP: 27101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001358403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 201450200 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 BUSINESS PHONE: (832) 384-1100 MAIL ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 FORMER COMPANY: FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060405 4 1 wf-form4_152762693514280.xml FORM 4 X0306 4 2018-05-25 0 0001358403 BELLICUM PHARMACEUTICALS, INC BLCM 0001295830 Musso Alan A C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800 HOUSTON TX 77030 0 1 0 0 CFO and Treasurer Common Stock 2018-05-25 4 S 0 6206 7.9707 D 26548 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person on June 7, 2017. Represents shares sold to satisfy tax liabilities and withholding obligations in connection with vesting of 14,706 shares of common stock from the Restricted Stock Awards granted to the Reporting Person on December 18, 2014. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.96 to $8.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth above. /s/ Alan A. Musso, Attorney-in-Fact 2018-05-29